Home >> Research Area >>Proteases/Proteasome>>HCV Protease>> Ciluprevir (BILN-2061)

Ciluprevir (BILN-2061)

Inhibitor of HCV NS3 protease CAS# 300832-84-2

Ciluprevir (BILN-2061)

Catalog No. BCC1482----Order now to get a substantial discount!

Product Name & Size Price Stock
Ciluprevir (BILN-2061): 5mg $414 In Stock
Ciluprevir (BILN-2061): 10mg Please Inquire In Stock
Ciluprevir (BILN-2061): 20mg Please Inquire Please Inquire
Ciluprevir (BILN-2061): 50mg Please Inquire Please Inquire
Ciluprevir (BILN-2061): 100mg Please Inquire Please Inquire
Ciluprevir (BILN-2061): 200mg Please Inquire Please Inquire
Ciluprevir (BILN-2061): 500mg Please Inquire Please Inquire
Ciluprevir (BILN-2061): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Ciluprevir (BILN-2061)

Number of papers citing our products

Chemical structure

Ciluprevir (BILN-2061)

3D structure

Chemical Properties of Ciluprevir (BILN-2061)

Cas No. 300832-84-2 SDF Download SDF
PubChem ID 6450803 Appearance Powder
Formula C40H50N6O8S M.Wt 774.93
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO
SMILES CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)OC4CC5C(=O)NC6(CC6C=CCCCCCC(C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O
Standard InChIKey PJZPDFUUXKKDNB-CJXSQDHESA-N
Standard InChI InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24?,27-,29+,33+,40-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Ciluprevir (BILN-2061) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ciluprevir (BILN-2061) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ciluprevir (BILN-2061)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.2904 mL 6.4522 mL 12.9044 mL 25.8088 mL 32.261 mL
5 mM 0.2581 mL 1.2904 mL 2.5809 mL 5.1618 mL 6.4522 mL
10 mM 0.129 mL 0.6452 mL 1.2904 mL 2.5809 mL 3.2261 mL
50 mM 0.0258 mL 0.129 mL 0.2581 mL 0.5162 mL 0.6452 mL
100 mM 0.0129 mL 0.0645 mL 0.129 mL 0.2581 mL 0.3226 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Ciluprevir (BILN-2061)

Ciluprevir is a selective inhibitor of NS3 protease with IC50 value of 3.0 nM [1].
NS3 (non-structural protein 3) protease is a protein whose C-terminal two-thirds contain a helicase and nucleic acid-stimulated NTPase activities and plays a pivotal role in HCV replication. It is reported that NS3 has regarded as a target to control HCV RNA replication via designing new drugs to inhibit it [2, 3].
Ciluprevir is a NS3 protease inhibitor and has a different affinity with the reported NS3 protease inhibitor VX-950. When using covalent adducts formation method, Svahn Gustafsson S found that ciluprevir showed faster association and slower dissociation kinetics [1].
NS3.4 protease inhibitor ciluprevir has potential for treating chronic HCV and robust antiviral activities have been reported. Furthermore, treatment HCV patients with ciluprevir showed significant HCV RNA reduction in plasma levels in clinical [4].
References:
[1].    Svahn Gustafsson, S., et al., Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants. J Med Chem, 2014. 57(5): p. 1802-11.
[2].    Howe, J.A., et al., Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infect Dis, 2014. 1(2): p. ofu078.
[3].    Susser, S., et al., Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. Antimicrob Agents Chemother, 2015.
[4].    Goudreau, N. and M. Llinas-Brunet, The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs, 2005. 14(9): p. 1129-44.

Featured Products
New Products
 

References on Ciluprevir (BILN-2061)

Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.[Pubmed:17002221]

Curr Opin Drug Discov Devel. 2006 Sep;9(5):606-17.

Hepatitis C virus (HCV) NS3.4A protease inhibitors have potential for treating chronic HCV disease. Robust antiviral effects have been reported for the three HCV NS3.4A inhibitors (BILN-2061 (ciluprevir), telaprevir (VX-950; Vertex Pharmaceuticals Inc./Janssen Pharnmaceutica NV/Mitsubishi Pharma Corp.) and SCH-503034; Schering-Plough Research Institute) that have been studied in clinical trials to date in HCV-infected patients, and new inhibitor molecules continue to appear on the horizon. Herein, toe relate the remarkable progress of these drug candidates to recent evidence that suggests HCV might depend on NS3.4A protease to subvert multiple innate cellular defense mechanisms.

Keywords:

Ciluprevir (BILN-2061),300832-84-2,Natural Products,HCV Protease, buy Ciluprevir (BILN-2061) , Ciluprevir (BILN-2061) supplier , purchase Ciluprevir (BILN-2061) , Ciluprevir (BILN-2061) cost , Ciluprevir (BILN-2061) manufacturer , order Ciluprevir (BILN-2061) , high purity Ciluprevir (BILN-2061)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: